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Abstract 
Respiratory infections by bacteria of the Burkholderia cepacia complex (Bcc) remain an important cause of morbidity 
and mortality among cystic fibrosis patients, highlighting the need for novel therapeutic strategies. In the present 
work we have studied the B. cenocepacia protein BCAL2958, a member of the OmpA‑like family of proteins, dem‑
onstrated as highly immunogenic in other pathogens and capable of eliciting strong host immune responses. The 
encoding gene was cloned and the protein, produced as a 6× His‑tagged derivative, was used to produce polyclonal 
antibodies. Bioinformatics analyses led to the identification of sequences encoding proteins with a similarity higher 
than 96 % to BCAL2958 in all the publicly available Bcc genomes. Furthermore, using the antibody it was experimen‑
tally demonstrated that this protein is produced by all the 12 analyzed strains from 7 Bcc species. In addition, results 
are also presented showing the presence of anti‑BCAL2958 antibodies in sera from cystic fibrosis patients with a clini‑
cal record of respiratory infection by Bcc, and the ability of the purified protein to in vitro stimulate neutrophils. The 
widespread production of the protein by Bcc members, together with its ability to stimulate the immune system and 
the detection of circulating antibodies in patients with a documented record of Bcc infection strongly suggest that 
the protein is a potential candidate for usage in preventive therapies of infections by Bcc.
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Introduction
The thickened mucus layer of the cystic fibrosis (CF) 
lung, with enhanced airway surface liquid volume absorp-
tion, reduced clearance and hypoxia gradients provides 
a habitat for opportunistic pathogens (Worlitzsch et  al. 
2002). This environment promotes host neutrophil inva-
sion with subsequent release of oxidants and proteases, 
such as myeloperoxidase (MPO) and neutrophil elastase 
(NE), causing progressive and continued lung tissue dam-
age (Downey et al. 2009; Cohen-Cymberknoh et al. 2013; 
Watt et  al. 2005; Worlitzsch et  al. 1998). Secreted and 
cell surface bacterial proteins are essential in mediating 
infection and inflammation processes by the host. Bind-
ing of these proteins to host cells is now recognized as 
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triggering inflammatory responses leading to the release 
of host cytokines like TNF-α and various interleukins, to 
combat the pathogen (Watt et al. 2005).
The Burkholderia cepacia complex (Bcc) comprises 
important opportunistic pathogens capable of caus-
ing life threatening lung infections among cystic fibrosis 
(CF) patients (Leitão et  al. 2010; Drevinek and Mahen-
thiralingam 2010). Despite advances in therapy, chronic 
infections with Bcc remains a problematic issue because 
these pathogens are very difficult to eradicate and have 
been associated with a faster decline of lung function, 
increased morbidity and mortality of patients (Mahen-
thiralingam et al. 2005; Hauser et al. 2011). No effective 
therapies are currently available to eradicate Bcc bacte-
ria from CF patients, as these are inherently resistant to 
the majority of antimicrobials clinically available (Leitão 
et al. 2008; Regan and Bhatt 2014). Therefore, therapeu-
tic strategies that protect patients against early Bcc lung 
infections represent attractive measures to control these 
infections.
In a previous work from our research group, the 
screening of a B. cenocepacia J2315-derived plasposon 
mutant library allowed the identification of BCAL2958 as 
a putative virulence determinant in the infection model 
Caenorhabditis elegans (Sousa et  al. 2008 and unpub-
lished results). The gene was identified after the rescue of 
a DNA fragment containing the inserted plasposon and 
surrounding DNA sequences, using previously described 
methods (Sousa et  al. 2008; Ramos et  al. 2010). Analy-
sis of the nucleotide sequence revealed that the plas-
poson was inserted in the intergenic region upstream 
BCAL2958 which encodes an outer membrane protein 
A (OmpA)-like protein. OmpA-like proteins from other 
gram-negative bacterial species are surface exposed pro-
teins that have been shown to occur at high copy number. 
These proteins have been associated with virulence, being 
involved in adhesion and invasion of host cells, induction 
of cell death, serum and antimicrobial resistance, and 
immune evasion (Krishnan and Prasadarao 2012; Smani 
et al. 2014). OmpA-like proteins from several pathogens, 
like the OprF from the CF pathogen Pseudomonas aer-
uginosa, have been associated with respiratory epithelial 
adhesion with cell activation through intracellular sig-
nalling pathways that results in release of cytokines and 
chemokines (Fito-Boncompte et al. 2011).
Since OmpA-like proteins have been pointed out as 
good candidates for vaccine development (Krishnan and 
Prasadarao 2012), we decided to investigate the immu-
nogenic properties of B. cenocepacia J2315 BCAL2958 
protein, envisaging its future exploitation as a immuno-
protectant against Bcc infections. In the present work we 
report bioinformatics studies predicting the occurrence 
of immunogenic epitopes on the protein, and on the 
conservation and occurrence of genes encoding OmpA-
like proteins in members of the Bcc with completed and 
publicly available genome sequences. These bioinformat-
ics studies were complemented by experimental data 
demonstrating that the protein is expressed by several 
strains based on western-blot carried out using an anti-
body raised against B. cenocepacia J2315 BCAL2958. 
Results are also presented showing the presence of 
antibodies against BCAL2958 in blood sera from 4 CF 
patients with a known record of Bcc infection. Results on 
the ability of the protein to stimulate human neutrophils, 
as evidenced by increased release of TNFα, elastase, mye-
loperoxidase, hydrogen peroxide, nitric oxide and cata-
lase by neutrophils upon exposure to BCAL 2958 are also 
presented. Results here presented strongly suggest that B. 
cenocepacia J2315 BCAL2958, encoding an OmpA-like 
protein, is a strong immunostimulant produced by Bcc, 
with potential usage as an immunoprotectant against Bcc 
infections.
Materials and methods
Bacterial strains, plasmids, and culture conditions
The bacterial strains and plasmids used in this work are 
listed in Table  1. When in use, Bcc strains were main-
tained in PIA (Pseudomonas Isolation Agar, BD) plates. 
Escherichia coli strains were maintained in LB (Lennox 
broth, Sigma) agar plates, supplemented with 150  µg 
ampicillin  ml−1, when appropriate. Unless otherwise 
stated, liquid cultures were carried out at 37  °C in LB 
liquid medium supplemented with the appropriate anti-
biotics, with orbital agitation (250 rev  min−1). Bacterial 
growth was followed by measuring the cultures optical 
density at 640 nm (OD640).
Molecular biology techniques
Total DNA was extracted from cells harvested from 
exponentially-growing liquid cultures of B. cenocepa-
cia strain J2315 using the High Pure PCR Template 
Preparation Kit (Roche). Plasmid isolation and purifica-
tion (Zymo Research), DNA amplification (Finnzymes), 
restriction and T4 DNA ligation (Fermentas), agarose gel 
electrophoresis, SDS-PAGE and E. coli transformation 
were carried out using standard procedures (Sambrook 
and Russel 2001). The primers used for amplification of 
BCAL2958 were UP-BCAL2958 (5′-TTGGATCCATG 
AATAAA CTTT-3′) and LW-BCAL2958 (5′-AAAAG 
CTTGTTTGCCGGAAC-3′), containing the BamHI and 
HindIII restriction sites (underlined), respectively, at 
their 5′end. Primers were designed based on the genome 
sequence of B. cenocepacia J2315 (available at the Sanger 
Institute Homepage; http://www.sanger.ac.uk/Projects/ 
B_cenocepacia), using the software Oligo Primer Analy-
sis v. 4, as previously described (Sousa et al. 2014).
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Cloning and overexpression of B. cenocepacia J2315 
BCAL2958
Plasmid pET23a+ and the 682 bp PCR product obtained 
using primers UP- BCAL2958 and LW- BCAL2958 
were digested with the restriction enzymes BamHI and 
HindIII. The BCAL2958 fragment was ligated into the 
BamHI/HindIII digested pET23a+, yielding pSAS6. 
pSAS6 construction was confirmed by sequencing. This 
plasmid allows the controlled expression of BCAL2958 
by the T7 promoter upon isopropyl β-D-thiogalactoside 
(IPTG) induction, producing a BCAL2958 derivative 
with a 6×  His-tag at the C-terminus. Plasmid pSAS6 
was transformed into E. coli BL21 (DE3) and the 6× His-
tagged protein was overexpressed by growing trans-
formed E. coli BL21 (DE3) in 250 ml of LB liquid medium 
(supplemented with 150  µg/ml ampicillin) at 30  °C and 
with orbital agitation (250  rpm). When the culture 
reached an OD640 of 0.6, 0.4 mM IPTG (final concentra-
tion) was added and the culture was further incubated 
for 2  h at 30  °C, 250  rpm. 6×  His-tagged BCAL2985 
overproduction was assessed by SDS-PAGE analysis 
and immunoblot experiments using a monoclonal anti-
polyhistidine peroxidase conjugate clone HIS-1 antibody 
(diluted 1:2000, SIGMA) as previously described (Sousa 
et al. 2013). Bacteria were then harvested by centrifuga-
tion for 5 min at 7000×g and 4 °C and the resulting pel-
let was resuspended in 8  ml sonication buffer (20  mM 
sodium phosphate, 500  mM NaCl, 20  mM Imidazole, 
pH 7.4). This cell suspension was aliquoted and stored at 
−80 °C until further processing.
Purification of B. cenocepacia J2315 6× His‑tagged 
BCAL2958
Bacterial cell suspensions were lysed by ultrasonic vibra-
tion with a Branson sonifier 250 (Branson), using 5 
sonication cycles of 30 s each at 50 % duty cycle. When 
processing cell suspensions to obtain the 6× His-tagged 
BCAL2958, 2 % (V/V) Triton X-100 and 0.5 mM phenyl-
methylsulfonyl fluoride (PMSF) were added prior to the 
last two sonication cycles. After sonication, non-soluble 
cell debris were removed by centrifugation at 12,000×g 
for 30  min at 4  °C. The cleared supernatants were col-
lected to new tubes and kept at 4 °C.
The 6×  His-tagged protein BCAL2958 was purified 
by affinity chromatography using a HisTrap FF column 
(GE Healthcare). After the initial equilibration of the col-
umn with 10 ml of Start buffer [sodium phosphate buffer 
1×, pH 7.4 (20 mM sodium phosphate, 500 mM NaCl); 
20  mM Imidazole; 0.1  % (V/V) Triton X-100; 0.5  mM 
PMSF], the 6× His-tagged BCAL2958 protein was eluted 
with Start buffer containing increasing imidazole con-
centrations (50, 70, 90, 150, 250, and 500 mM). Aliquots 
(1 ml) of the collected fractions of each protein were ana-
lysed by SDS-PAGE, and those containing the purified 
Table 1 Bacterial strains and plasmids used in this work
Strain or plasmid Genotype or description References or source
Strains
 B. cepacia LMG18821 Cystic fibrosis clinical isolate (Australia), MLST ST5 Mahenthiralingam et al. (2000)
 B. contaminans IST408 Cystic fibrosis clinical isolate (Portugal), MLST ST96 Richau et al. (2000)
 B. multivorans LMG16660 Govan C1576, Cystic fibrosis clinical isolate (UK), Glasgow epidemic reference, MLST ST27 Mahenthiralingam et al. (2000)
 B. multivorans LMG18825 Ryley CF‑A1‑1, Cystic fibrosis clinical isolate (UK), South Wales outbreak, MLST ST15 Mahenthiralingam et al. (2000)
 B. cenocepacia 
LMG16656
Govan J2315, Cystic fibrosis clinical isolate (UK), ET12 lineage reference strain, genome 
sequenced, MLST ST28
Govan and Deretic (1996)
 B. cenocepacia R‑1448 Cystic fibrosis clinical isolate (Canada) Mil‑Homens et al. (2010)
 B. cenocepacia 
LMG18829
Speert PC184, Cystic fibrosis clinical isolate (USA), Midwest strain, MLST ST40 Mahenthiralingam et al. (2000)
 B. cenocepacia R‑4194 Cystic fibrosis clinical isolate Mil‑Homens et al. (2010)
 B. cenocepacia 
LMG16654
Govan J415; Cystic fibrosis clinical isolate (UK), MLST ST34 Mahenthiralingam et al. (2000)
 B. stabilis LMG14294 Cystic fibrosis clinical isolate (Belgium), MLST ST50 Mahenthiralingam et al. (2000)
 B. vietnamiensis R‑5143 Cystic fibrosis clinical isolate Prof. Gerd Döring
 B. dolosa LMG18944 LiPuma PC688, Cystic fibrosis clinical isolate (USA) Coenye et al. (2001)





 E. coli BL21 (DE3) F− ompT hsdSB (rB
−mB
−) dcm gal λ(DE3). Stratagene
Plasmids
 pET23a+ Cloning/expression vector, T7 promoter, C‑terminal 6× His‑Tag, Apr Novagen
 pSAS6 pET23a+ with BCAL2958 gene cloned downstream of T7 promoter This study
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proteins were dialysed overnight at 4  °C in a 10  kDa 
cutoff Slide-A-Lyzer Dialysis Cassette (Pierce) against 
sodium phosphate buffer 1× (pH 7.4). Protein concentra-
tion was estimated by the method of Bradford (Bradford 
1976), with bovine serum albumin fraction V (BSA, Nzy-
tech) as standard.
In order to produce polyclonal antibodies against 
6×  His-tagged BCAL2958, endotoxin contaminations 
were removed from the protein purified samples using 
the Detoxi-Gel ™ endotoxin removing gel (Thermo Sci-
entific) following the supplier´s instructions and eluting 
protein samples with 1× Phosphate Buffered Saline (PBS) 
(137  mM NaCl, 2.7  mM KCl, 10  mM Na2PO4, 2.4  mM 
KH2PO4). The level of endotoxin in the purified 6× His-
tagged BCAL2958 protein was estimated using the Pierce 
LAL chromogenic endotoxin quantitation kit (Thermo 
Scientific) according to the manufacturer instructions. 
Purified samples with endotoxin levels below 0.2 EU/ml 
were used. Production and purification of a polyclonal 
goat antibody anti-6×  His-tagged BCAL2958 were per-
formed by the commercial company SICGEN (Portugal) 
after receiving the protein purified as described above.
Human serum samples
The serum samples S1 and S2 were collected from 2 CF 
patients infected with Bcc bacteria who attend the Hospi-
tal Santa Maria (Lisbon, Portugal), while serum samples 
S3 and S4 were obtained from two CF patients infected 
with Bcc who attended the Hospital de D. Estefânia (Lis-
bon, Portugal). Upon blood processing and serum recov-
ery, serum samples were stored at −80  °C until further 
use. A pool of human blood serum from healthy persons, 
used as control, was obtained commercially (Sigma).
CF patients blood sera immunoreactivity against the 
BCAL2958 protein
Purified 6×  His-tagged BCAL2958 and BSA (used as a 
negative control, Nzytech) were loaded into 12.5 % SDS-
PAGE gels and electrophoresed for 1  h at 150  V using 
standard procedures (Sambrook and Russel 2001). The 
gels were then incubated in transfer buffer (48 mM Tris, 
39 mM glycin, 20 % (V/V) methanol, 0.04 % (W/V) SDS, 
pH 9.2) for 15  min and the proteins electrotransferred 
to nitrocellulose (NC) membranes (PALL corporation) 
using a Trans-Blot® SD (BIORAD) device apparatus at 
15  mA for 1  h. After protein transfer, NC membranes 
were blocked overnight at 4 °C with 5 % (W/V) skim milk 
(DIFCO) in PBS 1×. Membranes were then probed with 
serum samples from CF patients (1:2000 dilution) or with 
a pool of human sera from healthy donors (1: 2000 dilu-
tion, SIGMA), for 3 h at room temperature. Membranes 
were washed with PBS 1×  containing Tween 0.05  % 
(V/V), and subsequently incubated with a secondary 
antibody horseradish peroxidase (HRP)-conjugated Rab-
bit anti-Human IgG (1:5000 dilution, SANTA CRUZ bio-
technology) for 1 h at room temperature. After removal 
of the secondary antibody and wash with PBS 1×/Tween 
0.05 % (V/V), membranes were treated with the peroxi-
dase substrate ECL (Sigma) and signals were detected 
using the FUSION Solo apparatus (Vilber Lourmat).
Enzyme‑linked immunosorbent assay (ELISA)
IgG levels against purified 6× His-tagged BCAL2958 in 
sera from CF patients with clinical history of Bcc was 
determined by enzyme-linked immunosorbent assay 
(ELISA). The OmpA was prepared at 2 µg/ml in 100 mM 
sodium carbonate buffer (pH 9.6) and 100 µl was applied 
per well to 96-wells ELISA plates (Greiner Microlon 600, 
Greiner Bio-One) and incubated overnight at 4  °C. The 
plates were blocked with 250 µl of 3 % BSA/PBS 1× over-
night at 4 °C. Serum samples were serially diluted (1:100 
to 1:100,000) in PBS 1 × supplemented with 3 % BSA and 
0.05 % Tween. The diluted serum was added to the plates 
and they were incubated 2  h at 25  °C. Then, the plates 
were washed with PBS 1× containing 0.05 % Tween and 
were incubated with 100  µl of HRP-conjugated rabbit 
anti-Human IgG (SANTA CRUZ Biotechnology) anti-
body at 1:3000 in PBS supplemented with 3 % BSA and 
0.05  % Tween. The plates were incubated 1  h at 25  °C. 
After washing the plates with PBS 1× containing 0.05 % 
Tween, it was added 100  µl of the peroxidase substrate 
3,3′,5,5′-tetramethylbenzidine (TMB, SIGMA). After 
20 min at 25 °C, the reaction was stopped by addition of 
100 µl of 0.5 M H2SO4. The plates were read at 450 nm 
in the SPECTROstar Nano microplate reader (BMG 
LABTECH). A pool of sera from healthy humans (Sigma) 
was used as control. Internal positive- and negative-con-
trols were included in each plate. All serum samples were 
analyzed in triplicate in two independent experiments, 
and the mean values were calculated.
Serum antibody concentrations were defined as end-
point titers and were calculated as the reciprocal of the 
highest serum dilution producing an OD450 above the 
cutoff value. The cutoff value was determined as the 
mean OD450  nm of the corresponding dilution of con-
trol sera plus 3 standard deviations. A titer of ≥1000 was 
considered positive for the ELISA.
Western blot analysis of BCAL2958 expression 
by Burkholderia cepacia complex bacteria
A volume of the total cell extracts corresponding to 
1  ml aliquot of a culture with an OD640 of 0.6 was dis-
solved in 40  µl of sample buffer [100  mM Tris base pH 
6.8, 4  % (W/V) SDS, 20  % (V/V) glycerol, 0.2  % (W/V) 
bromophenol blue, 200 mM DTT], incubated for 5 min 
at 100  °C, and separated by 12.5  % SDS-PAGE. After 
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electrophoresis, proteins were electrotransferred onto 
NC membranes (PALL corporation) using a Trans-Blot® 
SD (BIORAD), as described above. Then, the membranes 
were blocked with 5  % (W/V) skimmed milk (DIFCO) 
in PBS 1×, overnight at 4  °C. The membrane was then 
probed with the primary Goat antibody anti-BCAL2958 
(1:3000 dilution, SICGEN) for 2 h at room temperature. 
Probing with the secondary antibody HRP—conjugated 
Mouse anti-Goat IgG (1:10,000 dilution, SANTA CRUZ 
biotechnology) was carried out for 1 h at room tempera-
ture. The membranes were treated with the peroxidase 
substrate ECL (Sigma). The chemiluminescence signals 
were detected using the FUSION Solo device (Vilber 
Lourmat).
Isolation and purification of human neutrophils from blood
Neutrophils were obtained from human blood samples, 
collected from 8 adult healthy male volunteers (mean age 
29 ± 4 years).
Neutrophils were isolated from EDTA anti-coagu-
lated venous blood as described previously (Costa et  al. 
2006) with some modifications. Briefly, the blood was 
centrifuged using Ficol Hypaque (Amersham Pharma-
cia, Piscataway, NJ, USA) density gradient at 1500  rpm 
(HERMLE, USA) for 25  min to remove mononuclear 
cells. Then, red blood cells were lysed using ACK lysis 
buffer (Sigma, St. Louis, MO, USA). The neutrophils sus-
pension was centrifuged at 2000  rpm (HERMLE, USA) 
for 10  min, the supernatant was discarded and cells 
were washed with Dulbecco’s modified eagle medium 
(DMEM) media (Lonza, Belgium). Finally, neutrophils 
were resuspended in DMEM and 10  % FBS (HyClone, 
UK) and cells were counted. Resulting neutrophil prepa-
rations were >98 % pure, as assessed by flow cytometry. 
More than 95 % of the neutrophils were viable as meas-
ured by trypan blue dye (ADWIC, Egypt) exclusion.
Activation of neutrophils by OmpA
Isolated neutrophils (1 × 105 cells/well) were activated by 
incubation with OmpA (2 µg/ml, as optimized). 100 ng/
ml Lipopolysaccharide (Sigma-Aldrich, Germany) was 
used as a positive control. Supernatant was collected 
after 1, 2, 4, 8, and 12  h, for measuring MPO, TNF-α, 
Elastase, Hydrogen peroxide and Catalase, using ELISA 
methodologies and the Griess reagent to measure NO.
Neutrophil mediators assessment
Nitric oxide (NO) was assessed using the Griess reagent 
based on methods previously described (Green et  al. 
1982). Hydrogen peroxide (H2O2) was measured using 
a colorimetric kit (Bio-diagnostic, Egypt) as previously 
described (Fossati et  al. 1980). Catalase was measured 
using a colorimetric kit (Bio-diagnostic, Egypt) according 
to Aebi (1984). Human myeloperoxidase (MPO), Tumor 
necrosis factor-α (TNF-α) and Neutrophil elastase were 
measured using the ELISA kits MPO (Boster Immu-
noleader, USA), Human TNF-α (Boster Immunoleader, 
USA) and elastase (ASSAY PRO, USA), respectively, 
according to the manufacturer’s instructions. Non-acti-
vated neutrophils were used as negative controls.
Bioinformatics analyses
Nucleotide and predicted amino acid sequences were 
analysed using bioinformatics tools resident at the 
National Center for Biotechnology Information (NCBI) 
and the ExPASy-Prosite websites. Searches for homolo-
gous sequences within the genomes of B. cenocepacia 
J2315 and other Burkholderia strains were carried out 
using the databases Integrated Microbial Genomes and 
Burkholderia Genome Database (Markowitz et  al. 2014; 
Winsor et al. 2008). The prediction of B cell epitopes was 
performed using the BepiPred Linear Epitope Prediction 
method, resident at immune epitope database (IEDB) 
analysis resource (Larsen et al. 2006). A window size of 7 
and a threshold of 0.35 were used. The threshold 0.35 was 
used because it is the point at which sensitivity/specific-
ity is maximized in BepiPred (Larsen et al. 2006). Amino 
acid sequence alignments were generated using the 
CLUSTAL Omega Alignment (Sievers et al. 2011).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
software. Paired Student’s t test between different treat-
ments as well as ANOVA among different activation 
time points were analysed. The data obtained were repre-
sented as mean ± S.D. Results with a P value <0.05 were 
considered significant.
Results
Identification of B. cenocepacia J2315 BCAL2958, a member 
of the OmpA family
The B. cenocepacia J2315 gene BCAL2958 was initially 
identified as a putative virulence determinant during 
the screening of a plasposon-derived mutant library 
performed with Caenorhabditis elegans as an infection 
model (Sousa et al. 2008). During the screening, a mutant 
strain named SJ2, impaired in its ability to kill the nema-
todes, was retained for further characterization. Based on 
methodologies previously described (Sousa et  al. 2008), 
a plasmid harbouring the chromosomal DNA sequences 
flanking the inserted plasposon was retrieved from B. 
cenocepacia SJ2 mutant.
Analysis of the nucleotide sequence and searches 
for homologous sequences within the genome of B. 
cenocepacia J2315 revealed that the plasposon was 
inserted in the intergenic region upstream BCAL2958 
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encoding an OmpA (outer membrane protein A)-like 
protein (Fig.  1a). The deduced amino acid sequence 
of BCAL2958 was found to contain the PFAM00691 
motif (Fig.  1b), thus being a putative member of the 
OmpA family of proteins. The fact that several OmpA-
like proteins from other bacterial pathogens have been 
regarded as potential vaccines prompted us to investi-
gate B. cenocepacia J2315 BCAL2958 as a future vaccine 
or vaccine component (Pore and Chakrabarti 2013; Jean-
nin et  al. 2002; Krishnan and Prasadarao 2012). First, 
we have performed bioinformatics analyses in order 
to gain further evidence of the presence of homologs 
within genomes of other Bcc bacteria, and also to other 
members of the Burkholderia genus. These analyses 
revealed a total of 10 putative OmpA-like proteins, une-
venly distributed within the analysed genomes (Fig.  2a; 
Table  2) that included the following publicly available 
genomes: B. cepacia GG4 and DDS 7H-2; B. multivorans 
ATCC17616; B. cenocepacia strains AU1054; HI2424, 
J2315, MCO-3, H111, DDS 22E-1 and DWS 37E-2; B. 
vietnamiensis G4; B. dolosa PC543, B. ambifaria strains 
AMMD and MCO-40-6; and B. lata 383. The amino acid 
sequences of BCAL2958 homologs were ≥91  % identi-
cal and were present in all the genomes analysed, as 
well as those of BCAL2645, BCAL3204 and BCAM0690 
(Fig. 2a, Table 2). BCAL0349 and BCAM2419 homologs 
were also present in all the genomes analysed, with 
amino acid identity percentages of at least 84 and 74 %, 
respectively (Fig.  2a; Table  2). The other four OmpA 
family members identified in our survey (BCAM0220, 
BCAM1550, BCAM2255 and BCAS0237) were absent, 
at different extent, in some Bcc genomes (Fig.  2a; 
Table 2).
In addition to the in silico results showing that 
BCAL2958 is encoded within all the Bcc genomes exam-
ined, we have also tested the expression of the protein by 
a panel of 12 Bcc strains by western-blot techniques. The 
panel included the following Bcc isolates from CF patients 
with different geographic origins: B. contaminans IST408; 
B. cenocepacia strains J2315, R-1448, R-4194, LMG18829, 
and LMG16654; B. multivorans LMG16660, and 
LMG18825; B. cepacia LMG18821; B. stabilis LMG14294; 
B. vietnamiensis R-5143; B. dolosa LMG18944 (kindly 
provided by Prof. Peter Vandamme, U. Ghent, Belgium). 
A goat polyclonal antibody commercially raised against B. 
cenocepacia J2315 BCAL2958 was used. A fraction con-
taining total proteins from the B. cenocepacia J2315 strain 
was used as positive control in the assay. This analysis 
BCAL2957                               BCAL2958 BCAL2959 BCAL2960 BCALr2960




Fig. 1 BCAL2958 is a putative OmpA‑like protein. a Genetic organization of the BCAL2958 gene locus. Open reading frames BCAL2957 (GyrA, DNA 
gyrase subunit A), BCAL2958 (OmpA, outer membrane protein A family protein), BCAL2959 (UbiG, 3‑demethylubiquinone‑9 3‑demethyltransferase), 
BCAL2960 (Gph, putative 2‑phosphoglycolate phosphatase), and BCALr2960 (SsrA, transfer‑messenger RNA) are represented in scale; b Alignment 
of amino acid sequences of the OmpA‑like proteins BCAL2958 from B. cenocepacia J2315, AAA22979 from Bordetella avium, P0A910 from E. coli 
K12 and PA1777 from P. aeruginosa PA01. The amino acid residues of the signal sequence are in light grey. The peptidoglycan (PG)‑binding motif is 
boxed in grey. Asterisks indicate the amino acid residues that are identical in all the proteins; one or two dots indicate semi‑conserved or conserved 
substitutions, respectively
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revealed that the antibody was able to detect the protein 
OmpA in all Bcc strains tested, revealing that this protein 
is commonly expressed in Bcc strains (Fig. 2b).
Analysis of the BCAL2958 amino acid sequence with 
ProtParam revealed that this protein has a predicted 
molecular weight of 23.9 kDa and a theoretical pI of 9.45. 
A signal peptide was predicted by LipoP 1.0 Server, with 
the cleavage site at the amino acid residue Ala22 (Table 2; 
Fig.  1b). The use of the CLUSTAL Omega bioinformat-
ics tool revealed an amino acid identity of BCAL2958 
of 52.06, 39.62, and 25  %, respectively, with the already 
described OmpA-like proteins from Bordetella avium, 
E. coli K12, and P. aeruginosa PAO1 (Fig.  1b) (Gentry-
Weeks et  al. 1992; Arora et  al. 2001; Sugawara et  al. 
2006). The inspection of the amino acid sequence also 
revealed the presence of the peptidoglycan (PG) bind-
ing motif NX2LSX2RAX2VX3L in the C-terminal domain 
of BCAL2958, spanning residues 146–161 (Fig.  1b). 
This motif is typical of OmpA-like proteins, and is usu-











1 2 3 4 5 6 7 8 9 10 11 12
a
b
Fig. 2 BCAL2958 is commonly expressed by Bcc strains. a Bioinformatics analysis of the presence, in the complete genome of 15 Bcc strains, of 
orthologues of the 10 proteins with the PF00691 domain identified in the B. cenocepacia J2315 genome. The % of identity of the orthologues is 
indicated as follows: higher than 90 % (filled square), higher than 80 % (filled square), higher than 70 % (filled square), or absence of the gene (open 
square); b Western blotting of Bcc strains probed with the Goat anti‑BCAL2958 antibody. Lanes 1—B. cenocepacia J2315; 2—B. contaminans IST408; 
3—B. vietnamiensis R‑5143; 4—B. cenocepacia R‑1448; 5—B. cepacia LMG18821; 6—B. dolosa LMG18944; 7—B. cenocepacia R‑4194; 8—B. multivorans 
LMG16660; 9—B. multivorans LMG18825; 10—B. cenocepacia LMG18829; 11—B. cenocepacia LMG16654; 12—B. stabilis LMG14294
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N-terminal region of BCAL2958 was predicted as vari-
able, with a particularly low identity in the case of the 
OmpA-like proteins from E. coli K12 and P. aeruginosa 
PAO1 (Fig. 1b).
Cloning, expression and purification of BCAL2958
The 682  bp PCR fragment corresponding to the 
BCAL2958 gene of B. cenocepacia J2315 was ampli-
fied using primers UP-BCAL2958 and LW-BCAL2958 
(Table  1) and cloned into the expression vector 
pET23a + under the control of the T7 promoter, creating 
pSAS6 (Table 1). For the overexpression of the protein as 
a 6×  His-tagged derivative, plasmid pSAS6 was trans-
formed into E. coli BL21 (DE3) and the overexpression 
was induced by addition of 0.4 mM IPTG. The overpro-
duced 6× His-tagged BCAL2958 protein was analysed by 
SDS-PAGE, followed by Western blot using an antibody 
specific for the BCAL2958 protein. This analysis revealed 
3 different molecular weight forms of the protein, with 
estimated molecular masses of approximately 29.5, 25.5, 
and 19.2  kDa (Fig.  3), in agreement with previously 
reported observations for other OmpA-like proteins 
(Subramaniam et  al. 2000) The first two values are in 
agreement with the predicted molecular masses of 25.5 
and 23.3  kDa for the native protein with a 6×  His-tag, 
of the pre-protein containing the signal peptide, and the 
mature protein without the signal peptide, respectively. 
No protein was detected by Western blot when using 
the cell extract prepared from E. coli cells grown without 
IPTG induction (Fig. 3a).
The recombinant protein was then purified to homoge-
neity by nickel affinity chromatography and the fractions 
containing the purified his-tagged protein were dialysed 
overnight against appropriate storage buffers and further 
studied. After purification, three forms of the protein 
were still apparent in the gel (Fig. 3b). The multiple bands 
could be due to different stages of processing of the pro-
tein, as previously described for other OmpA proteins 




c http://www.cbs.dtu.dk/services/LipoP/. SPI signal peptide (signal peptidase I); SPII lipoprotein signal peptide (signal peptidase II); NP no signal peptide
d http://blast.ncbi.nlm.nih.gov/Blast.cgi
e http://tools.immuneepitope.org/bcell/. Bepipred Linear Epitope Prediction method
Protein Domainsa MWb Signal  
sequencec
Conservationd B cell epitopes average 
(predicted peptides)e
BCAL0349 BON (PF04972) 32.8 1–36 (SPI) >84 % in Bcc 0.498 (13)
OmpA (PF00691) >72 % in Burkholderia genera
<66 % with other bacteria
BCAL2645 Gly‑zipper YMGG 
(PF13441)
21.6 1–21 (SPII) >94 % in Bcc 0.433 (11)
OmpA (PF00691) >71 % in Burkholderia genera
<60 % with other bacteria
BCAL2958 OmpA (PF00691) 23.9 1–22 (SPI) >96 % in Bcc 0.362 (11)
>87 % in Burkholderia genera
<77 % with other bacteria
BCAL3204 OmpA (PF00691) 18.7 1–20 (SPII) >91 % in Bcc 0.336 (9)
>82 % in Burkholderia genera
<70 % with other bacteria
BCAM0220 OmpA (PF00691) 25.3 1–22 (SPII) Not conserved 0.369 (12)
BCAM0690 OmpA (PF00691) 22.6 NP >92 % in Bcc 0.083 (11)
>74 % in Burkholderia genera
<84 % with other bacteria
BCAM1550 OmpA (PF00691) 17.7 1–18 (SPII) Not conserved 0.319 (10)
BCAM2255 OmpA (PF00691) 18.3 1–26 (SPII) Not conserved 0.120 (5)
BCAM2419 OmpA (PF00691) 22.9 1–17 (SPII) >74 % in Bcc 0.363 (12)
>35 % in Burkholderia genera
<36 % with other bacteria
BCAS0237 OmpA (PF00691) 23.1 1–17 (SPII) Not conserved 0.382 (13)
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(Gentry-Weeks et  al. 1992; Subramaniam et  al. 2000): 
(1) pro-OmpA, OmpA precursor that contains the signal 
peptide and is located in the cytoplasm or associated with 
the cytoplasmic membrane; (2) imp-OmpA, immature 
processed OmpA without the signal peptide and located 
in the periplasm or attached to the inner face of the outer 
membrane, and (3) mature OmpA. The molecular mass 
determined by SDS-PAGE of the OmpA protein is larger 
than the predicted molecular mass of the deduced amino 
acid sequence of OmpA. The small discrepancy between 
the apparent molecular mass determined by SDS-PAGE 
and that predicted for the protein has been reported in 
other outer membrane proteins (Manchur et al. 2011).
The BCAL2958 protein is immunoreactive with sera 
from CF patients infected with Bcc
To examine whether the BCAL2958 protein is capable 
of inducing an immune response in CF patients during 
infection with Bcc, we performed the detection of IgG 
antibodies against the protein in 4 serum samples col-
lected from CF patients with culture-confirmed Bcc 
infections. The purified 6×  His-tagged BCAL2958 
protein reacted with all the serum samples (Fig.  4a), 
suggesting that this protein is exposed to the immuno-
logical system of the CF patients during the infection 
and is immunogenic. Bovine serum albumin fraction V 
was used as negative control (Fig.  4a). No reactivity of 
BCAL2958 protein was observed when using a sample 
of a pool of serum from healthy individuals (Fig. 4). The 
IgG antibody titers of each serum sample was deter-
mined by ELISA and revealed that all the samples from 
CF patients infected with Bcc had IgG titers higher than 
4300, while the sample of a pool of serum from healthy 
individuals presented IgG titers below the threshold 
(Fig. 4b).









kDa M     3
a b
Fig. 3 Expression and purification of BCAL2958 and analysis of the 
specificity of a goat antibody against BCAL2958. a Analysis of the 
specificity of a goat antibody against BCAL2958 by Western‑blot. 
Lanes 1—Total proteins from non‑induced E. coli BL21 (DE3); 2—total 
proteins from IPTG induced E. coli BL21 (DE3). b Purification analysis 
of the recombinant protein BCAL2958 from E. coli BL21 (DE3) by SDS‑
PAGE. Lanes M—PageRuler Plus Prestained Protein Ladder (Thermo 
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Fig. 4 The OmpA‑like BCAL2958 protein is immunoreactive with sera 
from CF patients infected with Bcc. a Western blotting of the purified 
recombinant protein BCAL2958 from B. cenocepacia J2315 probed 
with the Human serum samples SCF1, SCF2, SCF3 and SCF4 from 
CF patients infected with Bcc bacteria, or a pool of human serum 
sample from healthy donors SH. The BSA protein was used in the 
assay as a negative control. Lanes M—Precision Plus Protein™ Dual 
Xtra Standard (BIO‑RAD); 1—purified recombinant BCAL2958 protein; 
2—albumin bovine fraction V (BSA, Nzytech). b IgG antibody levels 
present on sera from CF patients infected with Bcc (SCF1, 2, 3 and 
4) and in healthy individuals (SH) against BCAL2958 protein. Serum 
antibody concentrations were defined as endpoint titers and were 
calculated as the reciprocal of the highest serum dilution producing 
an OD450 nm above cutoff value. The cutoff value was determined 
as the mean OD450 nm of the corresponding dilution of control 
sera plus 3 standard deviations (dashed line). A titer of ≥1000 was 
considered as positive
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The OmpA‑like protein BCAL2958 interferes 
with neutrophils activity
Neutrophils are the first line of innate immune defense 
against infectious diseases (Kumar and Sharma 2010). 
Additionally, activated neutrophils regulate immune 
response by providing signals for the activation and 
maturation of both macrophages and dendritic cells 
(DCs) (Chertov et  al. 1997, Bennouna et  al. 2003). So, 
neutrophils can act as a transport vehicle for intracel-
lular pathogens and deliver antigens to DCs, and thus 
play an important role in activation of T cell immune 
response by DCs (Megiovanni et  al. 2006). Therefore, 
in this study we analyzed the response of neutrophils to 
the BCAL2958 protein by measuring the tumor necrosis 
factor alpha (TNFα), neutrophil elastase (NE), myeloper-
oxidase (MPO), hydrogen peroxide (H2O2), nitric oxide 
(NO) and catalase levels.
After incubation with BCAL2958 protein, neutrophil 
secreted TNFα, elastase and NO secretion increased sig-
nificantly in all incubation times, suggesting an activation 
of the neutrophils (Fig. 5b, d, e).
BCAL2958 enhanced also MPO secretion from neutro-
phils, mainly during the first 2 h of incubation (Fig. 5f ). 
In contrast, no significant change in H2O2 concentration 
was observed (Fig. 5a). Neutrophils azurophilic granules 
contain a rich supply of the enzyme MPO that in combi-
nation with H2O2 and chloride constitutes a potent anti-
microbial system (Klebanoff 2005). Therefore, our results 
suggest that due to high levels of secretion of MPO dur-
ing the first 2  h of incubation, the neutrophils released 
H2O2 could have been consumed directly into other 
forms of oxygen radicals.
Significant increases of catalase were also observed 
after all neutrophil activation times in response to 
BCAL2958 (Fig. 5c). The catalase detoxifies H2O2 to oxy-
gen and water, reducing also the H2O2 levels produced by 
the neutrophils (Roos et al. 1980).
Discussion
Despite the emergence of novel therapies (Chmiel et  al. 
2014), bacterial lung infections remain the main cause of 
morbidity and mortality in CF patients, with P. aerugi-
nosa as the leading pathogen. For this pathogen, eradi-
cation is hardly achieved in chronically infected patients 
by antibiotic treatments (Ciofu et al. 2013; Chmiel et al. 
2014), while early infection eradication is more eas-
ily achieved (Schelstraete et  al. 2013). Therefore, novel 
approaches preventing either the adherence or the colo-
nization of the CF lung by bacterial pathogens are envis-
aged as the most promising eradication strategies (Regan 
and Bhatt 2014). In the case of Bcc infections, no objec-
tive guidelines for eradication strategies are available, as 
these pathogens are inherently resistant to the majority 
of antibiotics (Regan and Bhatt 2014).
Predominant immunogenic components of pathogenic 
bacteria are potential candidates for the design of novel 
serological diagnosis tests and the development of strat-
egies for efficient immune protection and eradication. 
OmpA-like proteins, which are important immunogenic 
components of the outer membrane of gram-negative 
bacteria, are promising candidates for such purposes. 
This is the case of the OmpA-like proteins such as the 
17 kDa OmpA from B. cenocepacia, OmpA from E. coli, 
OmpA from Shigella flexneri 2a and the OprF from P. aer-
uginosa (Makidon et al. 2010; Guan et al. 2015; Pore and 
Chakrabarti 2013; Baumann et al. 2004). The knowledge 
of the potential immunogenicity of these OmpA-like pro-
teins prompted us to investigate the B. cenocepacia J2315 
BCAL2958 protein, previously identified by our group 
when analysing the relative virulence of a B. cenocepacia 
random plasposon mutant library (unpublished results).
Bioinformatics analysis of the BCAL2958 deduced 
amino acid sequence revealed the presence at the pro-
tein C-terminus of the conserved peptidoglycan-binding 
(critical for the noncovalent interaction with the under-
lying PG layer in the periplasm (De Mot and Vander-
leyden 1994; Koebnik et  al. 2000), while its N-terminal 
part exhibited a low or null similarity to the other outer 
membrane proteins analysed. OmpA-like proteins typi-
cally have highly variable and heterogeneous N-terminal 
regions.
Inspection of the genomes of members of the Bcc with 
completed and publicly available genome sequences 
revealed several putative ORFs encoding OmpA-like 
proteins. In particular, all the inspected Bcc genomes 
revealed the presence of BCAL2958 orthologues with an 
identity higher than 96  %. In a previous work using an 
immunoproteomic approach with a pool of serum sam-
ples from Bcc-infected CF patients, Shinoy et  al. (2013) 
observed that OmpA-like proteins were immunoreactive 
and were present in strains of B. cenocepacia and B. mul-
tivorans. In the present work, we furthered this observa-
tion, showing that the BCAL2958 protein is expressed 
by 12 strains belonging to 7 different Burkholderia spe-
cies isolated from CF patients with different geographi-
cal origins, based on western blot experiments using an 
antibody raised against B. cenocepacia J2315 BCAL2958. 
Conservation of this surface antigen among Bcc strains 
is critical for its possible use either as a diagnostic rea-
gent or a vaccine. OmpA-type porins from several other 
bacterial species have been shown to be highly immuno-
genic, inducing specific humoral and cytotoxic responses, 
even in the absence of adjuvants (Jeannin et al. 2005). In 
this work, we found that the BCAL2958 protein of B. 
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cenocepacia J2315 is recognized by all the four CF serum 
samples tested, revealing that this protein can elicit a 
humoral immune response in CF patients.
Recombinant purified forms of OmpA has been 
shown to activate both macrophages (Soulas et  al. 
2000), dendritic cells (DCs) (Jeannin et  al. 2000; Lee 
et al. 2010) and neutrophils (Mantovani et al. 2011) in a 
receptor-dependent manner, suggesting that OmpA func-
tions as a molecular pattern that activates the immune 
system. In CF lung disease, neutrophils are the most rapid 
and predominant innate immune cell type to transmi-
grate into the infected CF airway compartment (Hector 
et al. 2016). Previously, we observed colocalization of Bcc 














































































































Fig. 5 The OmpA‑like protein BCAL2958 interferes with neutrophils activity. a Level of hydrogen peroxide produced by neutrophils in response 
to OmpA at different incubation times; b Level of nitric oxide produced by neutrophils in response to OmpA at different activation times; c Level 
of catalase produced by neutrophils in response to OmpA at different activation times; d Level of elastase produced by neutrophils in response 
to OmpA at different activation times; e Level of TNF‑α produced by neutrophils in response to OmpA at different activation times; f Level of MPO 
produced by neutrophils in response to OmpA at different activation times. Asterisks significant as compared to negative control at P < 0.05
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infected CF lung tissue samples who underwent trans-
plantation, suggesting Bcc persistence within neutrophils 
in CF patients (Sousa et al. 2007). Therefore, we analysed 
the effect of BCAL2958 on human neutrophils. Neutro-
phils have surface receptors that have evolved to recog-
nize and bind to surface bacterial constituents and trigger 
the cell to engulf the bacterium and induce the secretion 
of biologically active molecules, such as cytokines (e.g. 
TNFα) and MPO (Kumar and Sharma 2010). Our results 
indicate that BCAL2958 protein induces the secretion of 
neutrophil TNFα, elastase, catalase and NO, suggesting 
an activation of the human neutrophils. The K. pneumo-
niae OmpA was also shown to up-regulate the secretion 
of cytokines (e.g. TNF-α, IL-1β, IL-10, and IL-12) from 
murine and human macrophages (Jeannin et  al. 2005). 
OmpA from E. coli was shown to be the direct target of 
neutrophil elastase (Belaaouaj et al. 2000).
Stimulation of neutrophils with outer membrane vesi-
cles (OMV) from serogroup B Neisseria meningitidis 
was reported to led to the production of TNF-α, IL-8, 
MIP-1α and MIP1-β, and to the activation and recruit-
ment of monocytes/macrophages at the site of inflamma-
tion. Thus, neutrophils may influence the phenomenon 
of macrophage differentiation into pro-inflammatory or 
anti-inflammatory subtype (Lapinet et  al. 2000). TNF-α 
released by activated neutrophils also plays an impor-
tant role in the maturation of DCs (Bennouna and Den-
kers 2005). Neutrophils are also reported to enhance 
specific, adaptive T and B cell responses by enabling the 
differentiation of monocytes and DCs into professional 
antigen-presenting cells (Cerutti et  al. 2013; Mantovani 
et al. 2011). Therefore, the observed effect of BCAL2958 
on neutrophil activation and on the most probable acti-
vation of other immune host cells, such as macrophages 
and T cells will be interesting to further enlighten the 
type of immune response of CF patients to the protein 
BCAL2958.
In conclusion, the presence of genes encoding 
BCAL2958-like proteins within Bcc genomes, together 
with the confirmed expression of the protein by multiple 
Bcc members and its immunoreactivity with serum sam-
ples from CF patients infected with Bcc renders this pro-
tein as a potential candidate for the development of novel 
strategies for immunoprotection against Bcc infections 
and/or a novel diagnostic method for early detection of 
Bcc infections. Future experiments involving studies on 
the immunization of mice with purified BCAL2958 will 
give critical information on this subject.
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